↓ Skip to main content

Dove Medical Press

Article Metrics

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives

Overview of attention for article published in Vascular Health and Risk Management, January 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter
facebook
2 Facebook pages

Readers on

mendeley
92 Mendeley
Title
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
Published in
Vascular Health and Risk Management, January 2016
DOI 10.2147/vhrm.s83088
Pubmed ID
Authors

Carrie McAdam-Marx, Karen White, Holly Gurgle, Holly E Gurgle

Abstract

Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone. Newer pharmacologic treatments for T2DM include glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Both the classes of medication are efficacious, exhibit positive effects on weight, and are associated with minimal risk of hypoglycemia. The purpose of this review is to compare the clinical trial and real-world effectiveness data of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors related to A1c reduction, weight loss, cost-effectiveness, cardiovascular outcomes, and safety in patients with T2DM. This review summarizes comparative evidence for providers who are determining which of the two classes may be the most appropriate for a specific patient.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 1%
Unknown 91 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 18%
Other 12 13%
Student > Bachelor 12 13%
Researcher 11 12%
Student > Postgraduate 10 11%
Other 18 20%
Unknown 12 13%
Readers by discipline Count As %
Medicine and Dentistry 42 46%
Pharmacology, Toxicology and Pharmaceutical Science 11 12%
Agricultural and Biological Sciences 5 5%
Nursing and Health Professions 4 4%
Economics, Econometrics and Finance 4 4%
Other 7 8%
Unknown 19 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2016.
All research outputs
#4,155,054
of 7,921,887 outputs
Outputs from Vascular Health and Risk Management
#233
of 399 outputs
Outputs of similar age
#145,959
of 269,495 outputs
Outputs of similar age from Vascular Health and Risk Management
#8
of 11 outputs
Altmetric has tracked 7,921,887 research outputs across all sources so far. This one is in the 27th percentile – i.e., 27% of other outputs scored the same or lower than it.
So far Altmetric has tracked 399 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,495 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.